Biofrontera Announces Restructuring Of Supply Agreement With Biofronter AG
Portfolio Pulse from Benzinga Newsdesk
Biofrontera Inc. (BFRI) has announced a significant restructuring of its supply agreement with Biofrontera AG, including a substantial reduction in the transfer price of Ameluz to Biofrontera AG. Additionally, control of all US clinical trials of Ameluz will transfer to Biofrontera Inc. effective June 1.
February 20, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biofrontera Inc. announces a major restructuring with Biofrontera AG, reducing Ameluz transfer price and taking over US clinical trials.
The restructuring of the supply agreement, particularly the reduction in the transfer price of Ameluz, is likely to improve Biofrontera Inc.'s financial margins on the product. Additionally, taking control of the US clinical trials could streamline operations and potentially accelerate the development process for Ameluz in the US market. These factors are generally positive for the company's outlook, suggesting a likely positive impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90